<DOC>
	<DOCNO>NCT01170650</DOCNO>
	<brief_summary>The purpose study compare progression-free survival ( PFS ) ( base upon investigator assessment use RECIST v1.1 ) participants platinum-resistant ovarian cancer receive combination therapy EC145 pegylated liposomal doxorubicin ( EC145+PLD ) participant receive PLD placebo .</brief_summary>
	<brief_title>Study Women With Platinum Resistant Ovarian Cancer Evaluating EC145 Combination With Doxil® ( PROCEED )</brief_title>
	<detailed_description>This Phase 3 clinical trial evaluate efficacy safety combination EC145 pegylated liposomal doxorubicin ( PLD ; available United States Doxil® outside United States Caelyx® ) compare PLD placebo . Enrollment 640 patient include approximately 500 folate receptor positive plan . EC145 drug specifically design enter cancer cell via folate vitamin receptor ( FR ) generally find normal cell . Experimental evidence show target receptor express virtually ovarian cancer . Early clinical evidence small number Phase I participant , subset participant complete single-arm Phase II study , interim data ongoing randomized Phase 2 study ( PRECEDENT ) suggest EC145 may antitumor effect woman platinum-resistant ovarian cancer EC145 alone combination PLD generally well-tolerated . This evidence suggest EC145 may useful chemotherapy platinum-resistant ovarian cancer . All participant undergo image FR-targeting investigational diagnostic agent EC20 screening period ass bind image agent EC20 tumor . This non-invasive procedure provide additional information utility use EC20 image identify subject FR molecular `` target '' prior treatment EC145 therapy .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Participants must sign approve informed consent form ( ICF ) . Participants must ≥ 18 year age . Participants must pathologyconfirmed epithelial ovarian , fallopian tube , primary peritoneal carcinoma . Participants must primary secondary platinumresistant ovarian cancer . Participants must least single ( RECIST v1.1defined ) measurable lesion . For purpose obtain RECIST v1.1 baseline scan , participant must radiological evaluation conduct 28 day prior begin study therapy ( PLD ) . NOTE : For participant history CNS metastasis , baseline radiological imaging must include evaluation head . Participants must prior debulking surgery . Participants must receive prior platinumbased chemotherapy management primary disease must receive 2 prior systemic cytotoxic regimen . Participants allow receive , require receive , one additional noncytotoxic antitumor agent ( eg , biologic cytostatic ) management ovarian cancer . Participants must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Participants must recover ( baseline/stabilization ) prior cytotoxic therapyassociated acute toxicity . Participants must adequate organ function include : 1 . Bone Marrow Reserve : 1 . Absolute neutrophil count ( ANC ) ≥ 1.5x10^9/L prior treatment . Participants maintenance dose granulocyte colony stimulate factor ( GCSF ) eligible . 2 . Platelets ≥ 100x10^9/L 3 . Hemoglobin ≥ 9 g/dL 4 . Use supportive care measure ( eg , use white blood cell [ WBC ] growth factor , antiemetic , epoetin ) follow ASCO guideline list www.asco.org . Participants receive full supportive care , include transfusion blood mandate clinical need ; however , transfusion administer sole purpose meeting study inclusion criterion time inform consent sign first dose EC145/placebo/PLD administer allow . 2 . Hepatic : Total bilirubin level &lt; 1.5 x ULN ALT , AST , GGT , alkaline phosphatase level &lt; 2.5 x ULN . 3 . Renal : Serum creatinine level ≤ 1.5 x ULN participant serum creatinine level 1.5 x ULN , creatinine clearance ≥ 50 mL/min/1.73m^2 4 . Cardiac : Left ventricular ejection fraction ( LVEF ) equal great institutional low limit normal . Patients refractory primary platinum therapy `` refactory '' define disease progression within 6 month first dose initial platinumbased therapy . Diagnosis `` tumor lowmalignant potential '' . Prior exposure PLD anthracycline therapy . Prior exposure FRtargeted therapy ( eg , EC145 , EC0225 , EC0489 , farletuzumab ) . Prior therapy vinorelbine ( Navelbine® ) vincacontaining compound . Prior abdominal pelvic radiation therapy radiation therapy &gt; 10 % bone marrow time past prior radiation therapy within past 3 year breast/sternum , dermal lesion , head neck . Recent ( i.e. , ≤ 6 week ) history abdominal surgery peritonitis Serious comorbidities ( determined investigator ) , limited , active congestive heart failure recent myocardial infarction . Patients require antifolate therapy management comorbid condition ( e.g. , rheumatoid arthritis ) exclude trial . Pregnant nursing . Concurrent malignancy require therapy ( exclude noninvasive carcinoma carcinoma situ ) . Symptomatic central nervous system ( CNS ) metastasis . Other concurrent chemotherapy , immunotherapy , radiotherapy , ancillary therapy consider investigational ( i.e. , use nonapproved indication ( ) context research investigation ) . Use low dose corticosteroid therapy ( e.g. , nausea prophylaxis ) acceptable ; however , concomitant tamoxifen therapy . Supportive care measure allow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>ovarian</keyword>
	<keyword>platinum-resistant</keyword>
	<keyword>Phase III</keyword>
	<keyword>EC145</keyword>
	<keyword>EC20</keyword>
</DOC>